(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Artemis II astronauts find hidden Easter eggs as they close in on the moon - 2One dead, six wounded in various crime-related shootings in Israel over the weekend
- 3Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- 4Easy to understand Tech: Cell phones for Old in 2024
- 5Vote In favor of Your Favored Web-based Visual depiction Administration
- WHO suspends Gaza medical evacuations after contractor killed by Israeli troops
- Child influencers helped power a booming industry. It's time for a reckoning.
- How Would You Like to Deal with Your Funds?
- Little Italy Mercato brings fresh food and community to downtown San Diego
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Disability rights activist and author Alice Wong dies at 51
- Lula’s former human rights minister formally accused of sexual misconduct
- Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
